Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.52

+0.4%

12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (19411)	3/22/2006 10:52:56 AM
From: Biomaven	Read Replies (1) of 52153

I just got hold of the ML report - they basically criticize ASISST-3 because of response rate rather than survival endpoint; ASISST-2 because it uses Iressa as a comparator; and ASSIST-3 because it's unlikely to show benefit as a single agent. They claim only $5 upside if all trials succeed, $13 downside. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next